JPWO2021077806A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021077806A5 JPWO2021077806A5 JP2021537127A JP2021537127A JPWO2021077806A5 JP WO2021077806 A5 JPWO2021077806 A5 JP WO2021077806A5 JP 2021537127 A JP2021537127 A JP 2021537127A JP 2021537127 A JP2021537127 A JP 2021537127A JP WO2021077806 A5 JPWO2021077806 A5 JP WO2021077806A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding
- peptide linker
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911015236.1 | 2019-10-24 | ||
CN201911015236.1A CN110669137B (zh) | 2019-10-24 | 2019-10-24 | 一种多特异性抗体及其制备方法和用途 |
PCT/CN2020/100892 WO2021077806A1 (zh) | 2019-10-24 | 2020-07-08 | 一种多特异性抗体及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022553464A JP2022553464A (ja) | 2022-12-23 |
JPWO2021077806A5 true JPWO2021077806A5 (zh) | 2023-07-19 |
Family
ID=69083964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021537127A Pending JP2022553464A (ja) | 2019-10-24 | 2020-07-08 | 多重特異性抗体とその製造方法および使用 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20210388077A1 (zh) |
EP (1) | EP3868788A4 (zh) |
JP (1) | JP2022553464A (zh) |
KR (1) | KR20220087402A (zh) |
CN (2) | CN110669137B (zh) |
AU (1) | AU2020371001A1 (zh) |
WO (1) | WO2021077806A1 (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110669137B (zh) * | 2019-10-24 | 2021-07-16 | 高新 | 一种多特异性抗体及其制备方法和用途 |
CN113214406B (zh) * | 2020-01-21 | 2022-08-02 | 苏州普乐康医药科技有限公司 | 一种结合gpc3融合蛋白的制备方法及应用 |
CN112336873B (zh) * | 2020-08-04 | 2022-04-19 | 华南理工大学 | 用于多特异性抗体递送的蛋白型纳米颗粒及其应用、制备方法 |
CN113527503A (zh) * | 2021-07-27 | 2021-10-22 | 福建医科大学 | 一种用于类风湿性关节炎的抗VEGF和TNF-α双特异性纳米抗体融合蛋白 |
CN114409797B (zh) * | 2021-12-24 | 2024-02-20 | 合肥天港免疫药物有限公司 | 重组抗体及其应用 |
CN116640224A (zh) * | 2022-02-16 | 2023-08-25 | 北京免疫方舟医药科技有限公司 | Cd137抗体和cd40l的融合蛋白及其应用 |
CN114380917B (zh) * | 2022-03-25 | 2022-06-14 | 南京融捷康生物科技有限公司 | 针对IL-17A和TNFα的双特异性单域抗体及其用途 |
WO2024067474A1 (zh) * | 2022-09-29 | 2024-04-04 | 上海宏成药业有限公司 | 靶向pd-1,ctla-4和vegf的三特异性抗体及其应用 |
CN115969997B (zh) * | 2022-12-19 | 2024-02-13 | 华润生物医药有限公司 | 一种靶向cldn18.2的抗体药物偶联物及其应用 |
CN116987198B (zh) * | 2023-09-28 | 2023-12-26 | 军科正源(北京)药物研究有限责任公司 | 一种靶向人pd-l1的融合蛋白及其用途 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5677425A (en) * | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
EP0590067A1 (en) * | 1991-06-14 | 1994-04-06 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
CN100497390C (zh) * | 2003-06-27 | 2009-06-10 | 比奥根艾迪克Ma公司 | 疏水-相互作用-层析或铰链区修饰对于均质抗体溶液的制备的用途 |
EP2535349A1 (en) * | 2007-09-26 | 2012-12-19 | UCB Pharma S.A. | Dual specificity antibody fusions |
RU2010151725A (ru) * | 2008-05-16 | 2012-06-27 | Аблинкс Нв (Be) | Аминокислотные последовательности, направленные против cхcr4 и других gpcr, и соединения, включаюшие их |
AR080793A1 (es) * | 2010-03-26 | 2012-05-09 | Roche Glycart Ag | Anticuerpos biespecificos |
EP2748202B1 (en) | 2011-08-23 | 2018-07-04 | Roche Glycart AG | Bispecific antigen binding molecules |
KR101723273B1 (ko) * | 2011-08-23 | 2017-04-04 | 로슈 글리카트 아게 | 2 개의 fab 단편을 포함하는 fc-부재 항체 및 이용 방법 |
GB201203051D0 (en) * | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
ES2923641T3 (es) | 2013-12-30 | 2022-09-29 | Epimab Biotherapeutics Inc | Inmunoglobulina con Fabs en tándem y usos de la misma |
CA2943167A1 (en) * | 2014-03-24 | 2015-10-01 | University Of Southampton | Modified antibodies containing modified igg2 domains which elicit agonist or antagonistic properties and use thereof |
GB201409558D0 (en) * | 2014-05-29 | 2014-07-16 | Ucb Biopharma Sprl | Method |
GB201411320D0 (en) * | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
AU2015283704A1 (en) * | 2014-07-01 | 2016-12-15 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
CN104592392B (zh) * | 2015-01-21 | 2018-08-28 | 武汉友芝友生物制药有限公司 | 一种双特异性抗体EpCAM×CD3的构建及应用 |
JP6862343B2 (ja) * | 2014-12-19 | 2021-04-21 | アブリンクス エン.ヴェー. | システイン結合ナノボディダイマー |
CN104558191B (zh) * | 2015-01-21 | 2020-08-21 | 武汉友芝友生物制药有限公司 | 一种双特异性抗体cd20×cd3的构建及应用 |
GB201521393D0 (en) * | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201522391D0 (en) * | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibody molecules |
ES2952951T3 (es) * | 2016-04-28 | 2023-11-07 | Biomunex Pharmaceuticals | Anticuerpos biespecíficos dirigidos a EGFR y HER2 |
JP7274417B2 (ja) | 2016-11-23 | 2023-05-16 | イミュノア・セラピューティクス・インコーポレイテッド | 4-1bb結合タンパク質及びその使用 |
CN107266567B (zh) * | 2017-06-05 | 2021-06-04 | 高新 | Lcrmp4单克隆抗体及其制备方法与应用 |
CN110669137B (zh) * | 2019-10-24 | 2021-07-16 | 高新 | 一种多特异性抗体及其制备方法和用途 |
-
2019
- 2019-10-24 CN CN201911015236.1A patent/CN110669137B/zh active Active
- 2019-10-24 CN CN202110525473.3A patent/CN113416258B/zh active Active
-
2020
- 2020-07-08 JP JP2021537127A patent/JP2022553464A/ja active Pending
- 2020-07-08 AU AU2020371001A patent/AU2020371001A1/en active Pending
- 2020-07-08 KR KR1020217015906A patent/KR20220087402A/ko unknown
- 2020-07-08 EP EP20878020.5A patent/EP3868788A4/en active Pending
- 2020-07-08 WO PCT/CN2020/100892 patent/WO2021077806A1/zh unknown
- 2020-07-08 US US17/292,739 patent/US20210388077A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021077806A1 (zh) | 一种多特异性抗体及其制备方法和用途 | |
US20210196821A1 (en) | Multimeric il-15-based molecules | |
US11459394B2 (en) | Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof | |
CA3089333C (en) | Anti-pdl1, il-15 and tgf-beta receptor combination molecules | |
JP7348899B2 (ja) | 多重特異性分子及びその使用 | |
JP6936497B2 (ja) | 多価Fv抗体 | |
CA3036564A1 (en) | Multispecific antibody molecules comprising lambda and kappa light chains | |
TW202012441A (zh) | Nk細胞接合抗體融合構築體 | |
KR20210091710A (ko) | PD-1 표적화 IL-15/IL-15Rα Fc 융합 단백질 및 병용요법에서의 이의 용도 | |
MX2014000816A (es) | Molecula fv de union de antigeno multivalente. | |
CA3201573A1 (en) | Targeted cytokine construct for engineered cell therapy | |
JP2022549186A (ja) | 高い標的密度の細胞に対する選択性を向上させた多量体抗体 | |
CA3059769A1 (en) | Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof | |
CA3113826A1 (en) | Csf1r/ccr2 multispecific antibodies | |
JPWO2021077806A5 (zh) | ||
WO2022100652A1 (zh) | 一种同时靶向cd3和cd137的融合蛋白及其制备方法和用途 | |
US20240018234A1 (en) | Bispecific binding agents binding to cldn18.2 and cd3 | |
US20230322952A1 (en) | Multispecific antibodies that bind both mait and tumor cells | |
JP2023539645A (ja) | Nkp30に結合する抗体分子およびその使用 | |
JP7513854B2 (ja) | Cldn18.2及びcd3に結合する二重特異性結合剤 | |
US20230295348A1 (en) | Composition and methods for the selective activation of cytokine signaling pathways | |
CN117003884A (zh) | 一种多靶向融合蛋白Rainbody及其制备方法和用途 |